Published in Arthritis Rheum on September 01, 2005
Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma. Arthritis Care Res (Hoboken) (2012) 1.84
Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol (2009) 1.50
Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study. Rheumatology (Oxford) (2009) 1.23
A significant proportion of children with morphea en coup de sabre and Parry-Romberg syndrome have neuroimaging findings. Pediatr Dermatol (2012) 1.17
Cytokine profiles in localized scleroderma and relationship to clinical features. Cytokine (2011) 0.98
Pediatric scleroderma: systemic or localized forms. Pediatr Clin North Am (2012) 0.96
Correlates of self-reported quality of life in adults and children with morphea. J Am Acad Dermatol (2014) 0.90
Prevalence of ocular manifestations in systemic sclerosis patients. Arch Med Sci (2013) 0.88
Localized scleroderma: clinical spectrum and therapeutic update. An Bras Dermatol (2015) 0.88
The Localized Scleroderma Cutaneous Assessment Tool: responsiveness to change in a pediatric clinical population. J Am Acad Dermatol (2013) 0.86
Sonographic evaluation of pediatric localized scleroderma: preliminary disease assessment measures. Pediatr Rheumatol Online J (2010) 0.86
Ocular involvement in children with localised scleroderma: a multi-centre study. Br J Ophthalmol (2007) 0.85
Gender and ocular manifestations of connective tissue diseases and systemic vasculitides. J Ophthalmol (2014) 0.83
Overlap between linear scleroderma, progressive facial hemiatrophy and immune-inflammatory encephalitis in a paediatric cohort. Eur J Pediatr (2015) 0.82
Parry-Romberg syndrome. J Dermatol Case Rep (2010) 0.80
Major histocompatibility complex class I and class II alleles may confer susceptibility to or protection against morphea: findings from the Morphea in Adults and Children cohort. Arthritis Rheumatol (2014) 0.79
Plaque morphea with neurological involvement—an extraordinary uncommon presentation. Clin Rheumatol (2013) 0.76
Recurrence of morphea after successful ultraviolet A1 phototherapy: A cohort study. J Am Acad Dermatol (2013) 0.76
Predictors of Longitudinal Quality of Life in Pediatric Localized Scleroderma. Arthritis Care Res (Hoboken) (2016) 0.75
Disabling pansclerotic morphea of childhood with extracutaneous manifestations. Indian J Dermatol (2013) 0.75
Mixed connective tissue disease presenting with progressive scleroderma symptoms in a 10-year-old girl. Postepy Dermatol Alergol (2013) 0.75
Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles. Semin Arthritis Rheum (2015) 0.75
Immunohistochemical studies of the kynurenine pathway in morphea. Int J Tryptophan Res (2013) 0.75
Adie's Tonic Pupil in Systemic Sclerosis: A Rare Association. Case Rep Ophthalmol Med (2015) 0.75
SLE with recurrent heart failure and a dermatological clue to another added possibility. BMJ Case Rep (2011) 0.75
Risk factors for morphoea disease severity: a retrospective review of 114 paediatric patients. Br J Dermatol (2014) 0.75
Treatment of localized scleroderma in childhood: Comment on the article by Zulian et al. Arthritis Rheum (2006) 0.75
Inflammatory arthritis, sacroiliitis, and morphea: evidence of a systemic inflammatory disease. Case Rep Rheumatol (2013) 0.75
A cross-sectional electromyography assessment in linear scleroderma patients. Pediatr Rheumatol Online J (2014) 0.75
[Scleroderma in childhood and adolescence. New aspects on classification, etiology and therapy]. Z Rheumatol (2008) 0.75
Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review. Clin Rev Allergy Immunol (2017) 0.75
Morphea in Middle Anatolia, Turkey: a 5-year single-center experience. Postepy Dermatol Alergol (2017) 0.75
Juvenile linear scleroderma with unique forms of renal involvement. Pediatr Nephrol (2009) 0.75
Longstanding epileptic encephalopathy and linear localized scleroderma: two distinct pathologic processes in an adolescent. Rheumatol Int (2008) 0.75
Primary and secondary central nervous system vasculitis: clinical manifestations, laboratory findings, neuroimaging, and treatment analysis. Clin Rheumatol (2014) 0.75
Morphea and Eosinophilic Fasciitis: An Update. Am J Clin Dermatol (2017) 0.75
Musculoskeletal MRI findings of juvenile localized scleroderma. Pediatr Radiol (2017) 0.75
International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol (2004) 14.06
De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum (2002) 4.98
Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med (2014) 4.70
Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med (2008) 4.58
Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med (2012) 4.15
2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) (2011) 3.66
EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis (2010) 3.47
A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum (2007) 3.32
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med (2012) 3.14
Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet (2008) 3.00
Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol (2004) 2.91
Revised nomenclature and classification of inherited ichthyoses: results of the First Ichthyosis Consensus Conference in Sorèze 2009. J Am Acad Dermatol (2010) 2.87
Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum (2005) 2.64
Dense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritis. Nat Genet (2013) 2.60
Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum (2002) 2.58
The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the disease activity core set. Arthritis Rheum (2005) 2.55
An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol (2011) 2.55
Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum (2009) 2.48
Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment. Proc Natl Acad Sci U S A (2010) 2.43
Evidence of the transient nature of the Th17 phenotype of CD4+CD161+ T cells in the synovial fluid of patients with juvenile idiopathic arthritis. Arthritis Rheum (2011) 2.24
A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis (2010) 2.22
Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford) (2005) 2.19
Colchicine myopathy and neuromyopathy: two cases with different characteristics. J Clin Rheumatol (2010) 2.17
Low level of genetic diversity in cultivated Pigeonpea compared to its wild relatives is revealed by diversity arrays technology. Theor Appl Genet (2006) 2.13
Molecular basis of the spectral expression of CIAS1 mutations associated with phagocytic cell-mediated autoinflammatory disorders CINCA/NOMID, MWS, and FCU. Blood (2003) 2.11
Rare NLRP12 variants associated with the NLRP12-autoinflammatory disorder phenotype: an Italian case series. Clin Exp Rheumatol (2013) 2.09
Results from a multicentre international registry of familial Mediterranean fever: impact of environment on the expression of a monogenic disease in children. Ann Rheum Dis (2013) 2.09
Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA (2010) 2.02
Parkes Weber syndrome, vein of Galen aneurysmal malformation, and other fast-flow vascular anomalies are caused by RASA1 mutations. Hum Mutat (2008) 2.00
Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease. Nat Genet (2011) 1.97
Access to biologic therapies in Canada for children with juvenile idiopathic arthritis. J Rheumatol (2012) 1.97
Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr (2005) 1.91
Early predictors of severe course of uveitis in oligoarticular juvenile idiopathic arthritis. J Rheumatol (2002) 1.90
Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nat Genet (2011) 1.84
Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2011) 1.83
Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol (2007) 1.82
Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther (2006) 1.78
International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum (2005) 1.75
A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum (2004) 1.71
Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol (2002) 1.71
B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum (2005) 1.71
Acute surgical abdomen as presenting manifestation of Kawasaki disease. J Pediatr (2003) 1.70
Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken) (2010) 1.70
Childhood chronic recurrent multifocal osteomyelitis: pamidronate therapy decreases pain and improves vertebral shape. J Rheumatol (2008) 1.69
Antinuclear antibody-positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. Arthritis Rheum (2011) 1.66
American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) (2011) 1.65
A new approach to clinical care of juvenile idiopathic arthritis: the Juvenile Arthritis Multidimensional Assessment Report. J Rheumatol (2011) 1.62
Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis (2012) 1.59
Juvenile polyarteritis: results of a multicenter survey of 110 children. J Pediatr (2004) 1.57
Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum (2007) 1.54
Peripheral neuropathy in pediatric systemic lupus erythematosus. Pediatr Neurol (2002) 1.52
EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation. Ann Rheum Dis (2010) 1.51
Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum (2003) 1.51
Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency. Clin Immunol (2004) 1.51
Development and testing of reduced joint counts in juvenile idiopathic arthritis. J Rheumatol (2009) 1.50
Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach. Rheumatology (Oxford) (2012) 1.49
Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum (2009) 1.47
Serum amyloid-A in Behçet's disease. Clin Rheumatol (2014) 1.47
Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. Arthritis Res Ther (2012) 1.46
Osteoprotegerin serum levels in Kawasaki disease: an additional potential marker in predicting children with coronary artery involvement. J Rheumatol (2005) 1.46
Safety and efficacy of once-weekly application of Etanercept in children with juvenile idiopathic arthritis. Rheumatol Int (2007) 1.44
Level of agreement between children, parents, and physicians in rating pain intensity in juvenile idiopathic arthritis. Arthritis Rheum (2006) 1.40
Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus. Ann Rheum Dis (2013) 1.39
SAPHO syndrome and transient hemiparesis in a child: coincidence or new association? J Rheumatol (2002) 1.39